I especially liked the below highlighted part of the article. They (ResAPP) developed a diagnostic phone app for respiratory disease and their company was pretty much instantly valued at $180 million dollars.
LDX market cap is about AUD $20 million dollars currently, with a current bank balance of AUD $10 million. We already have multiple functional respiratory diagnostic devices with a fast developing customer-base.......but do we have a phone app (apparently we have the in-house ability to develop phone applications: https://lumosdiagnostics.com/services/app-cloud).?
If we don't have a phone app, we should develop one and 10x our market cap instantly to ~AUD $180 million dollars.
LDX Price at posting:
4.0¢ Sentiment: Buy Disclosure: Held
